BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23160483)

  • 1. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
    Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
    Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Determination of thresholds values for platelet serotonin and urinary 5-HIAA concentrations for the biological diagnosis of digestive neuroendocrine tumors].
    Padelli M; Bruno C; Lemarchand J; Vourc'h P; Andres C; Blasco H; Benz-de Bretagne I
    Ann Biol Clin (Paris); 2019 Apr; 77(2):161-168. PubMed ID: 30998196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker.
    Tohmola N; Itkonen O; Sane T; Markkanen H; Joenväärä S; Renkonen R; Hämäläinen E
    Clin Chim Acta; 2014 Jan; 428():38-43. PubMed ID: 24211728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
    Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
    QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors.
    Tirosh A; Nilubol N; Patel D; Kebebew E
    Endocr Pract; 2018 Aug; 24(8):710-717. PubMed ID: 30084688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors.
    Khan TM; Garg M; Warner RR; Uhr JH; Divino CM
    Pancreas; 2016 Aug; 45(7):1032-5. PubMed ID: 26684860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
    Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
    Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
    Sen Gupta P; Grozinsky-Glasberg S; Drake WM; Akker SA; Perry L; Grossman AB; Druce MR
    Clin Endocrinol (Oxf); 2014 Feb; 80(2):246-52. PubMed ID: 23790044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurokinin A levels predict survival in patients with stage IV well differentiated small bowel neuroendocrine neoplasms.
    Diebold AE; Boudreaux JP; Wang YZ; Anthony LB; Uhlhorn AP; Ryan P; Mamikunian P; Mamikunian G; Woltering EA
    Surgery; 2012 Dec; 152(6):1172-6. PubMed ID: 23102678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues.
    Gut P; Ruchała M
    Neuro Endocrinol Lett; 2019 Dec; 40(7-8):315-318. PubMed ID: 32304367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors.
    Gregersen T; Grønbæk H; Worsøe J; Schlageter V; Laurberg S; Krogh K
    Scand J Gastroenterol; 2011 Jul; 46(7-8):895-902. PubMed ID: 21623673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classification of low-grade neuroendocrine tumors of midgut and unknown origin.
    Van Eeden S; Quaedvlieg PF; Taal BG; Offerhaus GJ; Lamers CB; Van Velthuysen ML
    Hum Pathol; 2002 Nov; 33(11):1126-32. PubMed ID: 12454818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
    Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
    Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.
    Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M
    Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours.
    van der Horst-Schrivers AN; Post WJ; Kema IP; Links TP; Willemse PH; Wymenga AN; de Vries EG
    Eur J Cancer; 2007 Dec; 43(18):2651-7. PubMed ID: 17825550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmatic and Urinary 5-Hydroxyindolacetic Acid Measurements in Patients With Midgut Neuroendocrine Tumors: A GTE Study.
    de Mestier L; Savagner F; Brixi H; Do Cao C; Dominguez-Tinajero S; Roquin G; Goichot B; Hentic O; Dubreuil O; Hautefeuille V; Walter T; Cadiot G
    J Clin Endocrinol Metab; 2021 Mar; 106(4):e1673-e1682. PubMed ID: 33382891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
    Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
    Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum pancreastatin: the next predictive neuroendocrine tumor marker.
    Rustagi S; Warner RR; Divino CM
    J Surg Oncol; 2013 Aug; 108(2):126-8. PubMed ID: 23775817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A reliable and simple method for the assay of neuroendocrine tumor markers in human urine by solid-phase microextraction-gas chromatography-triple quadrupole mass spectrometry.
    Monteleone M; Naccarato A; Sindona G; Tagarelli A
    Anal Chim Acta; 2013 Jan; 759():66-73. PubMed ID: 23260678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.